Form 4: Puma Biotechnology Executive Douglas M. Hunt Sells Shares Under 10b5-1 Plan

Douglas M. Hunt, Senior Vice President of Regulatory Affairs at Puma Biotechnology, sold 4,349 shares of common stock at an average price of $3.2685 on July 2, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On July 2, 2024, Douglas M. Hunt, Senior Vice President of Regulatory Affairs at Puma Biotechnology, sold 4,349 shares of common stock.
• The sale was executed under a pre-arranged 10b5-1 trading plan adopted on December 14, 2020.
• The shares were sold at a weighted average price of $3.2685, with individual transactions ranging from $3.2601 to $3.3101.
• Following the transaction, Hunt directly owns 136,864 shares of Puma Biotechnology common stock.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing regarding an insider stock sale under a pre-arranged plan. It doesn't convey any particularly positive or negative sentiment about the company's prospects.

Industry Context

This is a routine disclosure of an insider stock sale under a pre-arranged trading plan, which is a common practice to avoid accusations of insider trading. It doesn't necessarily reflect a change in the executive's confidence in the company.

Stakeholder Impact

• The stock sale could have a minor negative impact on shareholders if it creates downward pressure on the stock price, although the effect is likely to be minimal given the relatively small number of shares sold.

Key Dates